Biomarkers in IgA nephropathy; an update to recent data

IgA Nephropathy and Significance of Immunostaining Data

An update on the treatment of IgA nephropathy.

PURPOSE OF REVIEW The treatment of IgA nephropathy (IgAN) has been limited by several controversies in the literature, including the benefits of corticosteroids in addition to optimized renin-angiotensin system blockers (RASBs), in those with lower estimated glomerular filtration rate (eGFR), or in different ethnic groups. Recent studies have attempted to address these issues. RECENT FINDINGS...

IgA nephropathy: an update on pathogenesis and classification.

IgA nephropathy is a primary glomerulopathy characterized by deposition of IgA containing immune deposits in the kidney. Its diagnosis is based on histopathologic and immunoflourescence studies on renal biopsy. The disorder is poorly understood. This review is focused on updates regarding its pathogenesis and discussion on a new proposed histopathological classification of IgA nephropathy.

iga nephropathy and significance of immunostaining data

0

Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.

IgA nephropathy (IgAN) is a common chronic glomerular disease that, in most patients, slowly progresses to ESRD. The immune and autoimmune responses that characterize IgAN indicate a potential benefit for corticosteroids. The 2012 Kidney Disease Improving Global Outcome (KDIGO) guidelines suggest giving corticosteroids to patients with rather preserved renal function (GFR>50 ml/min per 1.73 m2)...